Compare JPMorgan Chase & Co (JPM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Merck & Co., Inc. — how do they compare? JPMorgan Chase & Co trades at $345.06 (market cap $900.78B), while Merck & Co., Inc. trades at $126.26 (market cap $307.25B). The key difference: JPMorgan Chase & Co is far larger — about 2.9× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| JPM | MRK | |
|---|---|---|
Market Cap | $900.78B | $307.25B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $129.52 |
52-Week Low | $282.84 | $77.60 |
Dividend Yield | 1.77% | 2.73% |
Enterprise Value | — | $350.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside a consensus price target of $372.73, signal positive momentum. Revenue growth is robust, rising to $181.85B in 2025, though net income dipped slightly to $57.05B. The stock benefits from institutional accumulation and media focus on CEO Jamie Dimon's economic insights.
The outlook for JPM remains favorable, driven by earnings resilience and sector leadership, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. With a moderate buy rating from analysts and a reasonable P/E of 14.52, the stock offers value, though investors should weigh macroeconomic headwinds against its solid fundamentals.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
